SE0301700D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0301700D0
SE0301700D0 SE0301700A SE0301700A SE0301700D0 SE 0301700 D0 SE0301700 D0 SE 0301700D0 SE 0301700 A SE0301700 A SE 0301700A SE 0301700 A SE0301700 A SE 0301700A SE 0301700 D0 SE0301700 D0 SE 0301700D0
Authority
SE
Sweden
Prior art keywords
novel compounds
therapy
processes
formula
preparation
Prior art date
Application number
SE0301700A
Other languages
English (en)
Swedish (sv)
Inventor
Rhonan Ford
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0301700(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to GBGB0312609.1A priority Critical patent/GB0312609D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301700A priority patent/SE0301700D0/xx
Publication of SE0301700D0 publication Critical patent/SE0301700D0/xx
Priority to UAA200510608A priority patent/UA83659C2/ru
Priority to TW093115168A priority patent/TW200508214A/zh
Priority to BRPI0410933-3A priority patent/BRPI0410933A/pt
Priority to RU2005136130/04A priority patent/RU2347778C2/ru
Priority to EP04735697A priority patent/EP1633717B1/de
Priority to MXPA05012883A priority patent/MXPA05012883A/es
Priority to DE602004023840T priority patent/DE602004023840D1/de
Priority to AU2004242626A priority patent/AU2004242626B2/en
Priority to CA2526884A priority patent/CA2526884C/en
Priority to ES04735697T priority patent/ES2333721T3/es
Priority to CN2004800222482A priority patent/CN1832925B/zh
Priority to HK06105844.1A priority patent/HK1085736B/en
Priority to JP2006508566A priority patent/JP4682128B2/ja
Priority to KR1020057023022A priority patent/KR101244971B1/ko
Priority to US10/558,898 priority patent/US7408065B2/en
Priority to PCT/SE2004/000836 priority patent/WO2004106305A1/en
Priority to AT04735697T priority patent/ATE446953T1/de
Priority to ARP040101893A priority patent/AR045691A1/es
Priority to UY28342A priority patent/UY28342A1/es
Priority to SA04250155A priority patent/SA04250155B1/ar
Priority to CO05120983A priority patent/CO5700720A2/es
Priority to ZA200509706A priority patent/ZA200509706B/en
Priority to IS8190A priority patent/IS8190A/is
Priority to NO20060001A priority patent/NO20060001L/no
Priority to US12/114,126 priority patent/US20090143354A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE0301700A 2003-06-02 2003-06-10 Novel compounds SE0301700D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds
UAA200510608A UA83659C2 (ru) 2003-06-02 2004-01-06 Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
TW093115168A TW200508214A (en) 2003-06-02 2004-05-27 Novel compounds
PCT/SE2004/000836 WO2004106305A1 (en) 2003-06-02 2004-06-01 New p2x7 receptor antagonists and their use
AT04735697T ATE446953T1 (de) 2003-06-02 2004-06-01 P2x7-rezeptorantagonisten und deren verwendung
ES04735697T ES2333721T3 (es) 2003-06-02 2004-06-01 Antagonistas de receptor p2x7 y su uso.
KR1020057023022A KR101244971B1 (ko) 2003-06-02 2004-06-01 신규한 ｐ2ｘ7 수용체 길항제 및 그의 용도
EP04735697A EP1633717B1 (de) 2003-06-02 2004-06-01 P2x7-rezeptorantagonisten und deren verwendung
MXPA05012883A MXPA05012883A (es) 2003-06-02 2004-06-01 Nuevos antagonistas del receptor p2x7 y su uso.
DE602004023840T DE602004023840D1 (de) 2003-06-02 2004-06-01 P2x7-rezeptorantagonisten und deren verwendung
AU2004242626A AU2004242626B2 (en) 2003-06-02 2004-06-01 New P2X7 receptor antagonists and their use
CA2526884A CA2526884C (en) 2003-06-02 2004-06-01 P2x7 receptor antagonists and their use
BRPI0410933-3A BRPI0410933A (pt) 2003-06-02 2004-06-01 novos antagonistas do receptor p2x7 e seu uso
CN2004800222482A CN1832925B (zh) 2003-06-02 2004-06-01 新的p2x7受体拮抗剂和它们的用途
HK06105844.1A HK1085736B (en) 2003-06-02 2004-06-01 P2x7 receptor antagonists and their use
JP2006508566A JP4682128B2 (ja) 2003-06-02 2004-06-01 新規ｐ２ｘ７受容体アンタゴニストおよびその用途
RU2005136130/04A RU2347778C2 (ru) 2003-06-02 2004-06-01 Новые антагонисты р2х7 рецепторов, способ их получения, фармацевтическая композиция, способ лечения и применение на их основе
US10/558,898 US7408065B2 (en) 2003-06-02 2004-06-01 P2X7 receptor antagonists and their use
UY28342A UY28342A1 (es) 2003-06-02 2004-06-02 Nuevos compuestos
ARP040101893A AR045691A1 (es) 2003-06-02 2004-06-02 Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
SA04250155A SA04250155B1 (ar) 2003-06-02 2004-06-09 عوامل مضادة لمستقبلة p2x7 الجديدة واستخدامها
CO05120983A CO5700720A2 (es) 2003-06-02 2005-11-29 Derivados de n-(quinolin-5l) alquilamida-sustituida; n-alquilquinolin-5-carboxamida-sustituida; n-alquilisoquinolin-5-carboxamida-sustituida; n-(isoquinolin-5-yl) alquilamida-sustituida y procesos para su preparacion
ZA200509706A ZA200509706B (en) 2003-06-02 2005-11-30 New P2X, receptor antagonists and their use
IS8190A IS8190A (is) 2003-06-02 2005-12-21 Ný P2X7 viðtakamótlyf og notkun þeirra
NO20060001A NO20060001L (no) 2003-06-02 2006-01-02 Nye P2X7-reseptorantagonister og deres anvendelse
US12/114,126 US20090143354A1 (en) 2003-06-02 2008-05-02 P2X7 Receptor Antagonists and Their Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds

Publications (1)

Publication Number Publication Date
SE0301700D0 true SE0301700D0 (sv) 2003-06-10

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds

Country Status (25)

Country Link
US (2) US7408065B2 (de)
EP (1) EP1633717B1 (de)
JP (1) JP4682128B2 (de)
KR (1) KR101244971B1 (de)
CN (1) CN1832925B (de)
AR (1) AR045691A1 (de)
AT (1) ATE446953T1 (de)
AU (1) AU2004242626B2 (de)
BR (1) BRPI0410933A (de)
CA (1) CA2526884C (de)
CO (1) CO5700720A2 (de)
DE (1) DE602004023840D1 (de)
ES (1) ES2333721T3 (de)
GB (1) GB0312609D0 (de)
IS (1) IS8190A (de)
MX (1) MXPA05012883A (de)
NO (1) NO20060001L (de)
RU (1) RU2347778C2 (de)
SA (1) SA04250155B1 (de)
SE (1) SE0301700D0 (de)
TW (1) TW200508214A (de)
UA (1) UA83659C2 (de)
UY (1) UY28342A1 (de)
WO (1) WO2004106305A1 (de)
ZA (1) ZA200509706B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
WO2006073361A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
EP1904474A4 (de) * 2005-07-13 2010-06-16 Astrazeneca Ab Neue pyridinanaloga
CN101232890A (zh) * 2005-08-01 2008-07-30 芬诺密克斯公司 制备杂环硼酸及其衍生物的方法
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EA200801108A1 (ru) * 2005-10-31 2008-10-30 Биолипокс Аб Триазолы, пригодные для лечения воспалений
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943225A1 (de) * 2005-11-01 2008-07-16 Biolipox AB Bei der behandlung von entzündungen geeignete pyrazole
US8007849B2 (en) 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
US20090298825A1 (en) * 2006-03-16 2009-12-03 Kelly Michael G Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
DK2001474T3 (en) * 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
CA2645551C (en) * 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
WO2008037626A1 (en) * 2006-09-28 2008-04-03 F. Hoffmann-La Roche Ag Quinoline derivatives with 5-ht-binding properties
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
MX2009005509A (es) * 2006-12-07 2009-06-03 Hoffmann La Roche 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
WO2008114002A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
AU2008236649B2 (en) * 2007-04-10 2013-05-02 H. Lundbeck A/S Heteroaryl amide analogues as P2X7 antagonists
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
BRPI0910253A2 (pt) 2008-03-07 2015-09-29 Hoffmann La Roche derivados de 2-aminoquinolina
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101598397B1 (ko) * 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
ES2380908T3 (es) 2009-04-14 2012-05-21 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su uso
CN105254557A (zh) * 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2013526496A (ja) 2010-05-14 2013-06-24 アフェクティス ファーマシューティカルズ アーゲー Ｐ２ｘ７ｒ拮抗剤の新規調製方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101995088B1 (ko) 2011-07-22 2019-07-02 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
PL2931717T3 (pl) 2012-12-12 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
KR102222220B1 (ko) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
WO2014115078A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EP2970271B1 (de) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7-modulatoren
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
AU2015269598B2 (en) * 2014-06-05 2019-11-14 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
CN106084068B (zh) * 2016-06-16 2019-07-16 郑州大学第一附属医院 一组肠菌素-抗生素衍生物及其应用
LT3609868T (lt) 2017-03-13 2023-12-11 Raqualia Pharma Inc. Tetrahidrochinolino dariniai kaip p2x7 receptoriaus antagonistai
EP3398941A1 (de) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
AU2020358948A1 (en) 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
CN115305282A (zh) * 2022-08-04 2022-11-08 烟台毓璜顶医院 一种用于AR-induced OD诊断和预后判别的靶点及治疗方法
WO2025180517A1 (zh) * 2024-03-01 2025-09-04 武汉人福创新药物研发中心有限公司 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
ATE148098T1 (de) 1991-02-21 1997-02-15 Sankyo Co Benzolderivate zum fördern der produktion des nervenwachstumsfaktors
PT720601E (pt) 1993-08-10 2001-02-28 Black James Foundation Ligandos de receptores de gastrina e cck
RO114445B1 (ro) 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
HUP0202214A3 (en) 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
WO2001037826A1 (en) * 1999-11-26 2001-05-31 Shionogi & Co., Ltd. Npyy5 antagonists
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
RU2347570C2 (ru) * 2001-07-02 2009-02-27 Н.В.Органон Тетрагидрохинолиновые производные
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
DE602004023840D1 (de) 2009-12-10
ES2333721T3 (es) 2010-02-26
TW200508214A (en) 2005-03-01
BRPI0410933A (pt) 2006-06-27
EP1633717A1 (de) 2006-03-15
SA04250155B1 (ar) 2008-11-15
CN1832925A (zh) 2006-09-13
WO2004106305A1 (en) 2004-12-09
JP2006526617A (ja) 2006-11-24
AU2004242626B2 (en) 2008-03-13
ATE446953T1 (de) 2009-11-15
AU2004242626A1 (en) 2004-12-09
KR20060015741A (ko) 2006-02-20
RU2005136130A (ru) 2006-06-27
CN1832925B (zh) 2010-05-05
UY28342A1 (es) 2004-12-31
CA2526884A1 (en) 2004-12-09
RU2347778C2 (ru) 2009-02-27
JP4682128B2 (ja) 2011-05-11
AR045691A1 (es) 2005-11-09
GB0312609D0 (en) 2003-07-09
KR101244971B1 (ko) 2013-03-18
IS8190A (is) 2005-12-21
ZA200509706B (en) 2006-12-27
MXPA05012883A (es) 2006-02-22
CO5700720A2 (es) 2006-11-30
NO20060001L (no) 2006-03-02
US20060293337A1 (en) 2006-12-28
US20090143354A1 (en) 2009-06-04
US7408065B2 (en) 2008-08-05
HK1085736A1 (en) 2006-09-01
UA83659C2 (ru) 2008-08-11
EP1633717B1 (de) 2009-10-28
CA2526884C (en) 2012-10-16

Similar Documents

Publication Publication Date Title
TW200508214A (en) Novel compounds
SE0302811D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
SE0202539D0 (sv) Compounds
TW200801003A (en) Novel compounds
SE0104140D0 (sv) Novel Compounds
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
SE0301653D0 (sv) Novel compounds
TW200800999A (en) Novel compounds
SE0202133D0 (sv) Novel compounds
IS6658A (is) Ný efnasambönd
SE0300480D0 (sv) Novel compounds
MY128924A (en) Novel compounds
AU2003228770A8 (en) Substituted pyrazolopyrimidines
SE0302139D0 (sv) Novel compounds
SE0401762D0 (sv) Novel compounds
SE0300119D0 (sv) Novel compounds
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
TW200833670A (en) Novel compounds 569
MXPA05012247A (es) Derivados de bencimidazol nuevos.
SE0303541D0 (sv) New compounds
TW200738659A (en) Novel compounds
SE0302546D0 (sv) New compounds
SE0102716D0 (sv) Novel compounds